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Abstract
While the use of high-resolution molecular typing in routine matching of human leukocyte antigens
(HLA) is expected to improve unrelated donor selection and transplant outcome, the genetic
complexity of HLA still makes the current methodology limited and laborious. Pyrosequencing™
is a gel-free, sequencing-by-synthesis method. In a Pyrosequencing reaction, nucleotide
incorporation proceeds sequentially along each DNA template at a given nucleotide dispensation
order (NDO) that is programmed into a pyrosequencer. Here we describe the design of a NDO
that generates a pyrogram unique for any given allele or combination of alleles. We present
examples of unique pyrograms generated from each of two heterozygous HLA templates, which
would otherwise remain cis/trans ambiguous using standard sequencing based typing (SBT) method.
In addition, we display representative data that demonstrate long read and linear signal generation.
These features are prerequisite of high-resolution typing and automated data analysis. In conclusion
Pyrosequencing is a one-step method for high resolution DNA typing.
Introduction
Solid organ transplantation and allogeneic stem cell trans-
plantation currently represent a common treatment for
end-stage organ failure and several hematological and
non-hematological malignances. Matching of patient and
unrelated donor for human leukocyte antigen (HLA) mol-
ecules significantly decreases the probability of graft rejec-
tion, graft vs. host disease and transplant-related mortality
[1]. However, the extensive diversity of the HLA genes
makes the identification of matched donors extremely
challenging. Although, in several instances it might not be
feasible to identify perfect matches, algorithms have been
developed that allow identification of likely histocompat-
ibility based on the molecular definition of individual
alleles [2,3]. This algorithm grades mismatches according
to the number of variant epitopes present between donor
and recipient. As histocompatibility is inversely correlated
with number of mismatches it is likely that sequence-
based information that provides the definitive informa-
tion about HLA allele identity will become increasingly
important in the future. High-resolution information
about HLA alleles identity is best achieved using sequenc-
ing-based methodology that could be performed using
high-throughput automated systems [4]. Although signif-
icant advancement has been made in resolution, automa-
tion, throughput and data analysis in DNA sequencing
and other polymorphism analysis techniques, the search
continues for more efficient methods that could resolve
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cis/trans ambiguities in highly polymorphic genetic sys-
tems such as HLA genes. Currently, commonly used HLA
molecular typing methods include sequence specific oli-
gonucleotide probes (SSOP), polymerase chain reaction
(PCR) using sequence specific primers (SSP) and
sequence based typing (SBT) [5]. Among them, SSOP
solely exploits DNA hybridization and, therefore, results
in the most cis/trans ambiguities. SSP can solve ambiguous
combinations if primers are designed to cover the gene-
omic region where the ambiguity is present. In this case,
amplification of the genomic region framed by two prim-
ers assures the occurrence in cis of these two regions. This
strategy, however, requires a large number of primers to
reach a desired resolution and cover various combina-
tions of ambiguous sites within HLA loci. SBT provides by
far the highest resolution and currently represents the
golden standard for high resolution DNA typing and
novel allele discovery. In addition, recent advances made
possible to perform SBT at a high throughput level in rou-
tine HLA typing laboratories [4]. The biggest challenge
that SBT of HLA alleles incurs is the resolution of intrinsic
cis/trans ambiguities that cannot be solved by SBT unless
time consuming cloning of individual genes is performed
[6]. This is because nucleotide incorporation proceeds
simultaneously along all DNA templates in a SBT reaction
[7].
Pyrosequencing™ [9-11] is a real-time, sequencing by syn-
thesis method catalyzed by four kinetically well-balanced
enzymes, DNA polymerase, ATP sulfurylase, luciferase,
and apyrase. It fundamentally differs from Sanger's
sequencing method in the order of nucleotide incorpora-
tion. Each nucleotide is dispensed and tested individually
for its incorporation into a nascent DNA template. Each
incorporation event is accompanied by release of pyro-
phosphate (PPi) in a quantity equimolar to the amount of
nucleotide incorporated. ATP sulfurylase quantitatively
converts PPi to ATP in the presence of adenosine 5' phos-
phosulfate. ATP then drives the luciferase-mediated con-
version of luciferin to oxyluciferin that generates visible
light in amounts that are proportional to the amount of
ATP. The light is detected by a charge coupled device
(CCD) camera and displayed as a peak in a pyrogram™.
Each peak height is proportional to the number of nucle-
otides incorporated. Unincorporated dNTP and excess
ATP are continuously degraded by Apyrase. After the deg-
radation is completed, the next dNTP is added and a new
Pyrosequencing cycle is started. As the process continues,
the complementary DNA strand is built up. To pyrose-
quence an unknown DNA sequence, a cyclic nucleotide
dispensation order (NDO) is generally used. As a result of
each cycle of dATP, dGTP, dCTP and dTTP dispensation,
one of the four dNTPs is incorporated into the DNA tem-
plate while the other dNTPs are degraded by Apyrase.
When a DNA sequence is known, non-cyclic NDOs can be
programmed with predictable pyrograms. Nucleotide
sequence is determined from the order of nucleotide dis-
pensation and peak height in the pyrogram.
Based on the programmable nucleotide incorporation
feature of Pyrosequencing, we set out to optimize Pyrose-
quencing for high resolution HLA DNA typing. Here we
describe the design of NDO that generates a pyrogram
that is unique for any given allele or combination of alle-
les. We present unique pyrograms generated from each of
the heterozygous HLA templates that would otherwise be
cis/trans ambiguous using sequencing based typing (SBT)
methods. We also present representative data that demon-
strate long read and linear signal generation. These fea-
tures are prerequisite of high-resolution typing and
automated data analysis. In conclusion, Pyrosequencing
can be used as a one-step method for high resolution DNA
typing and could be applied in several settings spanning
from HLA typing in support of donor/recipient selection
to become a complement to comprehensive immunoge-
netic profiling in several clinical setting where other
aspects of immune polymorphism need to be explored
[8].
Results
Design of nucleotide dispensation order (NDO) that 
generates unique pyrogram for any allele or combination 
of alleles
Two types of nucleotide dispensation can be used to pyro-
sequence a homozygous HLA template. An in-phase dis-
pensation results in incorporation of nucleotides into all
templates at the same base pair position(s). A negative
dispensation results in no incorporation of any nucle-
otide, generating background signal (zero peak) only.
Introducing negative dispensations at different positions
results in different pyrograms from the same homozygous
template [11]. In addition to in-phase and negative dis-
pensations, it is possible to exploit out-of-phase dispensa-
tion to pyrosequence heterozygous DNA templates. Out-
of-phase dispensation results in nucleotide incorporation
along one allele, which put the sequencing reaction ahead
of the other allele. Nucleotide incorporation can become
in-phase again at various downstream positions, which
can be controlled by NDO. Figure 1 shows five NDOs
designed to sequence heterozygous genomic regions of
the HLA-class II locus, DRB1. In this case, the goal is to the
differentiate DRB1*11011, 13011 (black bars) combina-
tion from the DRB1*0319, 1320 (Red bars) whose
sequences are only different at positions 5'-298-299-3'. All
NDOs start with nucleotide incorporation at position 5'-
286-3' and end at or after nucleotide incorporation at
position 5'-299-3' of both alleles. Each pyrogram peak
represents the sum of nucleotide incorporation at each
nucleotide dispensation step, into all DNA templates in
the same reaction mixture in either in-phase or out-of-Journal of Translational Medicine 2003, 1 http://www.translational-medicine.com/content/1/1/9
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NDO optimization Figure 1
NDO optimization. Sequences of DRB1*11011, 13011 and DRB1*1111, 1306 are shown on the top (5'-286-305-3'). NDO 1 to 
NDO 5 are designed to pyrosequence these two pairs of heterozygous templates. X-axis represents the NDO. G, A, T and C 
represent the dNTP that is dispensed at each. Alphabetical numbers represent the dispensation step. E.g. the first step dis-
penses dATP. Y-axis represents theoretical peak height, shown as number of nucleotide incorporated into the two molecules 
of template alleles at each nucleotide dispensation step. Black peaks represent signals generated from DRB1*11011, 13011. 
Red peaks represent signals generated from DRB1*1111, 1306.
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phase fashion. NDO 1 requires the least number of nucle-
otide dispensations but it generates the same theoretical
pyrogram from both templates. NDO 2, which is a typical
cyclic NDO, generates unique theoretical pyrograms from
each template but it requires more nucleotide dispensa-
tions than the other four NDOs, partly due to the inclu-
sion of four negative dispensations. NDO 3 generates
unique theoretical pyrograms from both templates at dis-
pensations 5, 18 and 19 and, requires less nucleotide dis-
pensations than NDO 2 because of the lack of negative
dispensations. NDO 4 also generates unique theoretical
pyrograms at three dispensations (dispensations 14, 15
and 16). In addition, it requires less nucleotide dispensa-
tions as compared to NDO 3 (18 Vs. 20). NDO 5 is the
most effective. It generates the most number of differen-
tial theoretical peak heights at positions 12, 14, 16 and 18,
and requires only 18 dispensations as well. Using this
technique, on one hand, each DNA template sequence
can generate different pyrograms. On the other hand, dif-
ferent DNA template sequences can generate identical
pyrograms. Our NDO design software automatically com-
pares a theoretical pyrogram generated by a given NDO
from any homozygous or heterozygous HLA template
sequence against that from all other homozygous or het-
erozygous HLA template sequences in the database (Shi et
al, unpublished results). Among the NDOs that result in
unique theoretical pyrogram, NDOs that produce that
shorter theoretical number of dispensations are chosen.
Pyrosequencing resolves intrinsic sequencing based typing 
(SBT) cis/trans ambiguity
Although high-resolution SBT of HLA allleles provides the
highest resolution, it cannot effectively solve many intrin-
sic cis/trans ambiguities unless coupled with time consum-
ing cloning of sequencing of individual clones. The
sequence difference between the two heterozygous tem-
plates at position 5'-298-299-3' as described in Figure 1,
for example, is a commonly encountered SBT ambiguous
example. In an effort to solve this SBT ambiguity, we
tested whether or not experimentally obtained pyrogram
matched the theoretical pyrogram predicted by NDO 5.
Figure 2 further illustrates NDO 5 step-wise. We chose to
place the 3' end of the Pyrosequencing primer just
upstream of another polymorphic site at 5'-286-3', desig-
nated reference polymorphic site. Out-of-phase NDO is
designed at the very first nucleotide dispensation. T is
incorporated in to template DRB1*110101 but not
DRB1*130101. The pyrogram output, as shown in Figure
3, demonstrates differential peak heights at all four theo-
retically different positions. Using the 11th peak adjacent
and upstream of the first differential peak (the 12th peak)
as a normalizer, we could observe that peak height ratios
at peaks 12, 14, 16 and 18 closely correlated with theoret-
ical peak height ratios proposed in Figure 1 (IDO 5). The
12th peak deviates from the prediction by 18%. The 14th
peak deviates by 13.5%. while both 16th and 18th peaks
demonstrated deviations from prediction close to 0%. As
an average the deviation from theoretical prediction was
7.9%. Figures 4 demonstrates another HLA-DRB1 SBT
ambiguity, DRB1*030101, 130101 Vs. DRB1*0319,
1320, that Pyrosequencing can solve. Using the upstream
adjacent peak (the 7th peak) as a normalizer, calculated
peak height ratios at peaks 8, 11, 14, 15 and 16 also
closely correlated with theoretical ratios with a deviation
range between 0% to 16.7% and an average deviation of
6.7%. These two examples demonstrate how Pyrose-
quencing can be used to quantify differences and there-
fore identify the cis/trans conformation of ambiguous
HLA heterozygous pairs that cannot be resolved by SBT.
The general principles for the design of NDO can be sum-
marized as follows: a primer is usually placed in proximity
upstream of the reference polymorphic site chosen to be
the one closest to the ambiguous polymorphic site to be
investigated. The first nucleotide dispensation is usually
out-of-phase. As a result, SBT ambiguity at one position is
generally magnified into pyrograms differences at multi-
ple peaks. This greatly enhances sensitivity and accuracy
in detection of peak height differences. In our experience,
ambiguities that cannot be solved by SBT within the HLA-
DRB1 locus can be consistently solved by unique Pyrose-
quencing NDO (Wang et al, unpublished results).
Long read and linear signal generation facilitates 
automated data analysis
The ability to perform long Pyrosequencing reads (length
of the genomic region investigated) is often necessary for
reasonable throughput. It is essential for achieving high
resolution when the reference polymorphic site down-
stream of the Pyrosequencing primer is distant from the
ambiguous site. In addition to the optimized NDO, the
PCR amplicons are designed to prevent background gen-
eration that could occur during a long Pyrosequencing
reaction. The pyrogram shown in Figure 5 is an example
of a linear and predictable reduction in signal generation
with low background signal generation through 72 nucle-
otide dispensations. The background signal ranges from
2% to 11% with an average of 6% of the signals immedi-
ately upstream and downstream (Figure 6, bottom panel).
The low background signal makes possible the discrimi-
nation of linear sequence-specific signals. One trend line
is plotted against the signals generated from dATP (Figure
6, Top panel). A similar trend line is plotted against the
signals generated from dGTP, dCTP and dTTP (Figure 6,
middle panel). The dATP trend line is plotted separately
because of its kinetics slightly faster than the other three
dNTPs. Note that both trend lines indicate high confi-
dence level with R2 greater than 95%. This linearity allows
the extrapolation of the actual peak height relative to the
dispensation point. Combining the two trend lines, theJournal of Translational Medicine 2003, 1 http://www.translational-medicine.com/content/1/1/9
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actual peak height can be extrapolated using the formula:
"Extrapolated peak = [Split Height + (Slope × Disp#)] ×
Nuc#". The extrapolated peak heights only vary from the
theoretical peak heights from 0% to 20%, averaging at
4.3%. This algorithm offers powerful aid to automated
data analysis of Pyrosequencing results.
The same NDO can generate unique pyrogram from DRB1*11011, 13011 and DRB1*1111, 1306 Figure 2
The same NDO can generate unique pyrogram from DRB1*11011, 13011 and DRB1*1111, 1306. The two heterozygous tem-
plates used are DRB1*11011, 13011 and DRB1*1111, 1306. The SBT ambiguous positions are at 5'-298-299-3'. The Pyrose-
quencing primer is high lighted in purple color with its 3' end located at 5'-285-3'. Nucleotide incorporation starts at position 
5'-286-3'. NDO is indicated on the left, from top to bottom. The nucleotides incorporated into each allele of template 
DRB1*11011, 13011 and each allele of template DRB1*11011, 13011 are highlighted in yellow at each nucleotide dispensation 
step except for the nucleotides involve in the ambiguities that are with the color red for  , green for   and black for  .
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Discussion
Pyrosequencing offers a new approach to data acquisition,
analysis and identification of known and unknown (new)
alleles, in particular in heterozygous conditions. This
method may represent a useful tool to the screening and
characterization of polymorphic genetic markers in sev-
eral clinical or experimental settings [12-24]. In addition,
Pyrosequencing has been applied for the study of gene
expression [23] and could be a usefull complement to
high throughput single nucleotide polymorphism identi-
fication system as a substitute to SBT [8,24]. Here we pro-
pose that Pyrosequencing may confront the most
challenging task of solving ambiguities in HLA typing by
SBT in heterozygous conditions. Although its reading
length is currently shorter than that routinely covered by
SBT, automated dNTP dispensation could compensate for
this limitation by controling simultaneous reactions in
multiple wells using primers that anneal to different loca-
tions of the template DNA. In fact, a reading length of 70
to 100 nucleotides allows the high-resolution genotyping
of Exon II of HLA-DRB1 (Wang et al, unpublished
results). NDOs can also be designed to achieve higher
throughput and lower genotyping resolution by introduc-
ing fewer numbers of out-of-phase dispensations (Wang
et al, unpublished results). Without automatization, it is
possible to process 96 to 384 wells PCR product by
Pyrosequencing within 4 hours. Constant improvements
in the chemistry for sample preparation for Pyrosequenc-
Pyrograms generated from two heterozygous DNA templates using the same NDO Figure 3
Pyrograms generated from two heterozygous DNA templates using the same NDO. Top pyrogram is generated from Pyrose-
quencing reaction in one well of a 96 well plate. Bottom pyrogram is generated from Pyrosequencing reaction in a separate 
well of a 96 well plate. The X axis of each pyrogram, from left to right, indicates the order of reagent addition. E represents 
enzyme. S represents substrate. The expected number of nucleotides incorporation into each pair of heterozygous DNA tem-
plate and actual peak height are indicated for the normalizer peaks and differential peaks below each pyrogram. At the bottom 
of the figure is shown expected ratio of peak heights and the ratio of normalized peak heights (in shadowed area).
DRB1*1111/DRB1*1306
DRB1*11011/DRB1*13011
P e a k  N u m b e r 123456789 1 0 1 1 1 2 1 3 1 4 1 5 1 6 1 7 1 8
N D O ESTCATCGTAGACGAGCGAG
Expected N˚ of 
Nucleotide 
Incorporation
1241
Peak Height 11.7 18.3 34.9 9.6
P e a k  N u m b e r 1 2 3 4 5 6 7 8 9 1 01 11 21 31 41 51 61 71 8
N D O ESTCATCGTAGACGAGCGAG
Expected N˚ of 
Nucleotide 
Incorporation
2132
Peak Height 19.5 10.3 25.7 16.O
Expected Peak 
Height Ratio
0.50 2.00 1.33 0.50
Actual Peak 
Height Ratio
0.59 1.73 1.33 0.50Journal of Translational Medicine 2003, 1 http://www.translational-medicine.com/content/1/1/9
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ing and Pyrosequencing [25-34] and the implementation
of automation devices http://www.pyrosequencing.com it
may be possible in the future to apply this technology
directly for routine typing of HLA and other immune
related genes characterized by extensive polymorphisms
[8].
Materials and Methods
DNA samples
Genomic DNA samples were locally available or obtained
from the International Histocompatibility Workshops
(IHW) cell lines panel, UCLA interchange panel and
samples.
PCR amplification
Each PCR amplification mixture of 50 µl contains 1 × PCR
buffer (made in house), 2 mM MgCl2, 0.2 mM of each
dNTP (purchased from Amersham Biosciences Inc.), 0.2
mM PCR primers, 2 U Taq DNA polymerase, and 250 ng
genomic DNA. Either forward or reverse primer is bioti-
nylated. PCR reaction starts with a 95°C denaturation for
5 minutes. This is followed with a 50-cycle thermal
cycling. Each cycle is programmed to include 30 seconds
denaturation at 95°C, 60 seconds annealing at appropri-
ate temperature, and a 10 seconds final extention at 72°C.
The PCR amplicon produced is enough for more 8 pyro-
sequencing reactions. The PCR amplicons used in this
The same NDO can generate unique pyrogram from DRB1*030101, 130101 Vs Figure 4
The same NDO can generate unique pyrogram from DRB1*030101, 130101 Vs. DRB1*0319, 1320. Top pyrogram is generated 
from Pyrosequencing reaction in one well of a 96 well plate. Bottom pyrogram is generated from Pyrosequencing reaction in a 
separate well of a 96 well plate. The X axis of each pyrogram, from left to right, indicates the order of reagent addition. E rep-
resents enzyme. S represents substrate. The expected number of nucleotides incorporation into each pair of heterozygous 
DNA template and actual peak height are indicated for the normalizer peaks and differential peaks below each Pyrogram. At 
the bottom of the figure is shown expected ratio of peak heights and the ratio of normalized peak heights (in shadowed area).
DRB1*030101/DRB1*130101
DRB1*0319/DRB1*1320
P e a k  N u m b e r 1 2 3 4 5 6 7 8 9 1 01 11 21 31 41 51 6
N D O GACTCTGATGCTGAGC
Expected N˚ of 
Nucleotide 
I ncorporation
2 3 320
Peak H eight 32 41 41 26 2
P e a k  N u m b e r 1234 56 7891 01 1 1 2 1 3 1 4 1 5 1 6
N D O GACTCTGATGCTGAGC
Expected N˚ of 
Nucleotide 
Incorporation
322 1 2
Peak H eight 62 39 37 1 8 35
Expected Peak 
Height Ratio
0.60 1 .50 1 .50 2.00 1 *
Actual Peak 
Height Ratio
0 .70 1.50 1.4 4 1.8 0 1.0 3
DRB1*03011 A C C T C C T G G A G C A G A
DRB1*13011 A C A TCCTGGAAGA CG
DRB1*0319 A C A TCCTGGAGCAGA
DRB1*1320 A C C T C C T G G A AGA CGJournal of Translational Medicine 2003, 1 http://www.translational-medicine.com/content/1/1/9
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work is 286 bp containing Exon II and the flanking intron
sequences.
Sample Preparation
Biotinylated PCR products are immobilized on streptavi-
din-coated Sepharose beads (Amersham Biosciences). 50
ul of Binding buffer (PyrosequencingAB) was added to the
50 ul of PCR product. Then 4 ul of streptavidin-coated
Sepharose beads was added and the mixture was vigor-
ously mixed at room temperature for 10 minutes. The
streptavidin-coated Sepharose bead and PCR mixture is
transferred to a filter plate (Amersham Biosciences) and
the Binding buffer is removed by vacuum. The bioti-
nylated DNA attached to the streptavidin-coated
Sepharose beads was denaturated in 50 ul of Denatura-
tion buffer (PyrosequencingAB) for 1 minute. The Dena-
turation buffer was removed by vacuum and DNA was
washed twice in 150 ul of Wash Buffer (Pyrosequenc-
ingAB). The DNA is resuspended in 50 ul of Annealing
buffer (PyrosequencingAB).
Pyrosequencing Reaction
40 ul of well mixed DNA was transferred to a 96-well
PSQ96 plate (PyrosequencingAB). The appropriate
sequencing primer was added in a volume of 5 ul using a
3 uM stock solution, resulting in 45 ul reaction volume.
The sequencing primer is allowed to anneal on a heat
plate set for 80°C for 2 minutes. Samples are allowed to
cool for 5 minutes at room temperature. Once samples
have cooled down the plate in placed on the Pyrose-
Linear signal generation through a 72 nucleotide dispensation Pyrosequencing run Figure 5
Linear signal generation through a 72 nucleotide dispensation Pyrosequencing run. Shown on the top in red is the Pyrose-
quencing primer sequence from 5' end to 3' end in the direction the red arrow points to. In this Pyrosequencing reaction, 
nucleotide incorporation into DRB1*1201, 1302 starts immediately downstream of the 3' end of Pyrosequencing primer and 
ends at the 3' end template sequence shown. The polymorphic positions are shown and underlined in blue. Pyrogram is shown 
below template sequence. Y-axis represents peak heights. X-axis represents NDO.
DRB1*1201015’-TGGAACAGCCAGAAGGACATCCTGGAAGACAG AGGCGCGCCGCGGTGGACACCTAT TTGCAGACACAACTAC-3’
DRB1*1302015’-TGGAACAGCCAGAAGGACATCCTGGAAGACGA GAGCGGGCCGCGGTGGACACCTAC CTGCAGACACAACTAC-3’              Journal of Translational Medicine 2003, 1 http://www.translational-medicine.com/content/1/1/9
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The percentage of each background peak over sequence-specific signal is calculated by dividing each background peak height  with the average peak height of the proximal upstream and downstream sequence-specific peak height Figure 6
The percentage of each background peak over sequence-specific signal is calculated by dividing each background peak height 
with the average peak height of the proximal upstream and downstream sequence-specific peak height. Top panel depicts a 
trend line generated from all the "A" peak heights of the pyrogram shown in Figure 5. Middle panel depicts a trend line gener-
ated from all the "G, C and T" peak heights of the pyrogram shown in Figure 5. R2 are shown on the upper right corners of 
both panels. Bottom depicts theoretical and extrapolated peak heights generated from the NDO and peak heights shown in 
top panel. The formula that is used is: Extrapolated peak= [Split Height + (Slope × Disp#)] × Nuc#. Average background is the 
average of all background signals. MAX background is the highest background signal over sequence specific signal. MIN back-
ground is the lowest background signal over sequence specific signal.
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quencer and the PSQ96 reagents are added to the SQA car-
tridge (PyrosequencingAB). NDO is automatically
designed using software developed at Pel-Freez Clinical
Systems. Pyrosequencing data output is quantified using
Peak Height Determination Software v1.1
(PyrosequencingAB).
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